AllerFund
Overview
AllerFund is a venture capital firm focused on creating social impact for the food allergy community. It invests in early-stage companies across various sectors, including biopharma, medical devices, diagnostics, and consumer products, with the goal of facilitating breakthroughs that can lead to cures and significantly enhance the quality of life for affected individuals. AllerFund's goal is to develop new therapies and products that will improve the lives of those living with food allergies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Amulet | Aug 2024 | Series A | Co-investor |
| ATANIS Biotech AG | Mar 2023 | Early Funding | Lead |
| Allergy Amulet | Aug 2024 | Series A | Co-investor |
| IgGenix | Feb 2023 | Series B | Co-investor |
| ANJO.AI INC. | Sep 2025 | Seed | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is AllerFund based?
AllerFund is headquartered in Scarsdale, New York, United States.
When was AllerFund founded?
AllerFund was founded in 2020.
How many portfolio companies does AllerFund have?
AllerFund has 7 portfolio companies in Caplight's dataset.
What are some companies in AllerFund's portfolio?
Portfolio companies visible on Caplight include Amulet, ATANIS Biotech AG, Allergy Amulet, IgGenix, ANJO.AI INC..
What was AllerFund's most recent investment shown here?
AllerFund's most recent investment in this portfolio sample was in ANJO.AI INC. in 2025.
What sectors does AllerFund focus on?
AllerFund focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Consumer & Commerce, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure.
What company stages does AllerFund focus on?
AllerFund typically invests at the Early stage.
What is AllerFund's AUM?
AllerFund's assets under management are estimated between $0.0 and $50.0M.